Views & Analysis Inside MoonLake’s raid on Merck KGaA’s inflammatory disease ... Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab.
News MoonLake launches, licensing in Merck KGaA's Cosentyx challe... There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KG
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends